Lineage Cell Therapeutics

Lineage Cell Therapeutics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Lineage Cell Therapeutics (LCTX) as of Nov 2, 2026 is -17.11. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -14.41 — a change of 18.80% (lower).

EV/FCF

-17.11

YoY

18.80%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Lineage Cell Therapeutics is 2025 -17.11 . EV/FCF (Enterprise Value to Free Cash Flow) of Lineage Cell Therapeutics was 2024 -14.41 . It decreases by 18.80% lower compared to the previous year.

The Lineage Cell Therapeutics EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-10.47 USD
Jan 1, 2019
-11.13 USD
Jan 1, 2020
-17.58 USD
Jan 1, 2021
-13.82 USD
Jan 1, 2022
514.10 USD
Jan 1, 2023
-12.09 USD
Jan 1, 2024
-14.41 USD
Jan 1, 2025
-17.11 USD
The Lineage Cell Therapeutics EV/FCF history
YEAREV/FCFYoY
-17.11+18.80%
-14.41+19.14%
-12.09-102.35%
514.10-3,819.68%
-13.82-21.37%
-17.58+57.91%
-11.13+6.37%
-10.47-4.63%
-10.97+33.99%
-8.19+17.32%
-6.98-23.10%
-9.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lineage Cell Therapeutics Stock analysis

What does Lineage Cell Therapeutics do? Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lineage Cell Therapeutics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Lineage Cell Therapeutics is -17.11 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Lineage Cell Therapeutics changed from -14.41 to -17.11, representing a 18.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Lineage Cell Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Lineage Cell Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lineage Cell Therapeutics

All Key Metrics — Lineage Cell Therapeutics